Global Health Leaders Converge in Nairobi for Landmark Symposium on Group B Streptococcus
This week marks a historic milestone in the fight against maternal and neonatal disease as the 2026 International Symposium on Streptococcus agalactiae Disease (ISSAD) opens in Nairobi. For the first time, this premier global conference is being held in East Africa, a region that bears some of the world’s highest burdens of the disease.
Running from February 23–25, 2026, the symposium brings together world-renowned scientists, public health officials, and vaccine developers to address the urgent threat posed by Group B Streptococcus (GBS).
The Silent Global Threat
Group B Streptococcus remains a major driver of infant mortality and maternal complications worldwide. The statistics highlighting the urgency of this gathering are stark:
•Carrier Rate: Approximately 1 in 5 pregnant women globally carries GBS.
•Annual Impact: GBS is responsible for roughly 400,000 cases of invasive disease in infants annually.
•Mortality: The disease is linked to an estimated 91,000 infant deaths and 46,200 stillbirths each year.
While decades of research have been dedicated to GBS, the current primary prevention strategy—administering antibiotics during labor—is often difficult to implement in resource-constrained settings. This has left a critical gap in protection for the most vulnerable populations in Sub-Saharan Africa and South Asia.
Shifting the Focus to Africa-Led Science
Hosting ISSAD 2026 in Nairobi is a strategic move to center the voices of those most affected. Dr. Hellene Barsosio, a Clinical Research Scientist at the KEMRI-LSTM Collaboration and co-chair of the event, emphasized that this year’s theme, "From Evidence to Action - Accelerating GBS Prevention in a Changing World," is about more than just theory.
"Hosting ISSAD 2026 in Nairobi presents a transformative opportunity to center the voices and experiences of the communities most affected by GBS disease," said Dr. Barsosio.
The conference highlights Kenya’s emergence as a regional health innovation hub, backed by world-class infrastructure and strong institutional partnerships like the Kenya Medical Research Institute (KEMRI) and the Ministry of Health.
Key Pillars of the 2026 Agenda
The three-day scientific program is designed to bridge the gap between research and real-world implementation. Key focus areas include:
1.Vaccine Development: Reviewing the latest progress in GBS vaccine candidates currently in clinical trials, which represent the best hope for a long-term solution.
2.Surveillance & Data: Addressing critical knowledge gaps in disease burden, particularly in low- and middle-income countries where data has historically been sparse.
3.Genomics & Innovation: Exploring how cutting-edge genomic research is reshaping our understanding of GBS transmission.
4.Policy Integration: Transitioning scientific evidence into actionable public health policies that can be sustained by local health systems.
A Collaborative Effort
The symposium is supported by an array of global and local partners, including Pfizer, KEMRI, the Bill & Melinda Gates Foundation (represented through various initiatives), and the Maternal Immunisation Readiness Network in Africa & Asia (MiRNA).
MiRNA, a collaborative network operating across nine countries, plays a vital role in ensuring that new life-saving vaccines can be seamlessly integrated into existing maternal health programs in countries like Ethiopia, Nigeria, and Pakistan.
As the conference concludes on February 25, the global health community looks toward a future where preventable GBS-related deaths are a thing of the past, driven by the research and leadership showcased this week in Nairobi.
Comments
Post a Comment